tradingkey.logo
tradingkey.logo
Search

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

ReutersSep 23, 2025 11:04 AM
facebooktwitterlinkedin

- Seres Therapeutics Inc MCRB.O:

  • SERES THERAPEUTICS ANNOUNCES FURTHER CONSTRUCTIVE FEEDBACK FROM FDA ON SER-155 PHASE 2 STUDY PROTOCOL AND IMPLEMENTS COST REDUCTION ACTIONS TO EXTEND CASH RUNWAY

  • SERES THERAPEUTICS INC - REDUCES WORKFORCE BY 25% TO EXTEND CASH RUNWAY

  • SERES THERAPEUTICS INC - WORKFORCE REDUCTION TO RESULT IN $1.0-$1.4 MILLION SEVERANCE COSTS

  • SERES THERAPEUTICS INC - SEEKS CAPITAL TO ADVANCE SER-155 PHASE 2 STUDY

  • SERES THERAPEUTICS INC: EXPECTS TO EXTEND CASH RUNWAY WELL INTO Q2 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI